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ABSTRACT 
BACKGROUND AND CONTEXT: In New Zealand, the highest prevalence of gout is in Maori and 
Pacific people. Counties Manukau District Health Board (CMDHB) has the highest Maori and Pacific 
population of any New Zealand District Health Board. A CMDHB study found that a high proportion of 
patients with gout were also at increased risk of cardiovascular disease. 
ASSESSMENT OF PROBLEMS: The primary objective was to examine whether the control of gout had 
changed over time at one clinic. The secondary objective was to assess the management of cardiovascu-
lar risk factors in patients with gout at that clinic.
RESULTS: The mean serum uric acid level of patients with gout in the practice had risen in comparison 
with a similar audit carried out in March 2009. This indicates that the control of gout for patients at the 
practice has worsened over time. Many patients had not had an annual serum uric acid test. 
STRATEGIES FOR IMPROVEMENT: A repeat uric acid level was scheduled for all patients with gout in 
the practice, with follow-up appointments to be arranged if the result was abnormal.
LESSONS: Gout is often suboptimally managed. Serum uric acid levels may only be tested when a 
patient presents with an acute attack of gout. Consideration should be given to a minimum of annual 
serum uric acid levels. Appropriate management of modifiable cardiovascular risk factors in this particular 
cohort is important and should be a particular focus of care.
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Background
Gout is one of the commonest forms of inflam-
matory arthritis in men and older women. It 
is caused by deposition of uric acid crystals in 
joints.1 Definitive diagnosis of gout is by aspira-
tion of a joint, but more often the diagnosis is a 
clinical diagnosis made in primary care.2 How-
ever, studies focusing on primary care have found 
that management of gout was suboptimal and did 
not comply with recent European League Against 
Rheumatism (EULAR) recommendations.2–5 In 
New Zealand, the Maori and Pacific population 
has a higher prevalence of gout than the popula-
tion with European ancestry.6–8 It is also known 
that this population group has a genetic predis-
position to the development of hyperuricaemia 
and gout.1 Counties Manukau District Health 
Board (CMDHB) has the highest Maori and 
Pacific population compared with other district 
health boards (DHBs) in New Zealand. There-
fore, optimal management of these conditions in 
this population group and DHB is of particular 
importance.9 Allopurinol has become established 
as the first-line treatment in New Zealand in 
long-term management of gout.2,10,11 Despite the 
ready availability of allopurinol, gout is a signifi-
cant cause of admissions to hospital and referral 
to Rheumatology Clinics in this area.5,12,13 Maori 
and Pacific men develop gout earlier in life than 
men in other ethnic groups, with the result that 
it impacts to a greater degree on their ability to 
work.6,14 Thus, it is important that primary care 
management of gout in CMDHB is optimal.
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The primary purpose of this study was to assess 
the management of gout in one primary care clinic 
and to establish whether or not the management of 
gout in this South Auckland practice has improved 
since a similar audit was conducted in 2009. An 
analysis of gout management between 2000 and 
2005 concluded that a diagnosis of gout warrants 
a cardiovascular risk assessment, due to the comor-
bidities associated with gout.2 Other studies have 
suggested that the presence of hyperuricaemia 
warrants investigation of associated diseases, such 
as diabetes and cardiovascular disease.15,16 Based on 
another recent study, 59% of patients with gout 
in CMDHB have an increased risk of a cardio-
vascular event within the next five years.17 These 
findings suggest an association between gout and 
cardiovascular risk factors. In view of this, the 
present study also assessed cardiovascular risk 
factor management in this group of patients.
Assessment of problem
A clinical audit was performed at a primary care 
clinic in South Auckland on 6 November 2012. 
The audit sought to identify registered patients 
who had been either classified as having gout at 
any time in their lives, or who had been pre-
scribed allopurinol or colchicine in the period 
from 6 November 2010 to 6 November 2012, in-
clusive. The lists of patients resulting from each 
search were then combined and sorted using their 
National Health Index (NHI) number. Duplicates 
were removed but a note of how the patient had 
been identified was included. Recorded data 
included age, gender, ethnicity, New Zealand 
Index of Socioeconomic Deprivation 2006 
(NZDep2006) quintile (a non-occupational index 
of socioeconomic deprivation where patients in 
quintile 1 are the least deprived and those in 
quintile 5 the most deprived),18 most recently pre-
scribed dose of allopurinol and colchicine, serum 
uric acid (SUA) level, and date of measurement. 
In connection with the cardiovascular disease risk 
score calculation, the following data were also 
tabulated: haemoglobin A1c (HbA1c), systolic 
blood pressure (SBP), high density lipoprotein 
(HDL) cholesterol, total cholesterol, smoking 
status, presence or absence of a family history of 
cardiovascular disease, and presence or absence of 
left ventricular hypertrophy on an electrocardio-
gram (ECG). The presence or absence of a family 
history of cardiovascular disease was determined 
as per the New Zealand Cardiovascular Guide-
lines.19 Where there was uncertainty or a lack of 
specificity, due to under-recording, a family his-
tory of cardiovascular disease was taken as being 
absent. A further search was made of the notes of 
patients who had been included on the grounds 
of having been prescribed allopurinol or colchi-
cine but who had not been given a formal classi-
fication of gout. Patients were excluded from the 
dataset if they had no mention of gout in their 
notes, or if a reason other than gout was given for 
being prescribed either allopurinol or colchicine. 
The level of control of gout was determined by 
the percentage of patients whose last measured 
SUA level was ≤0.36 mmol/L. 
Cardiovascular risk scoring was calculated using 
a formula based on the Framingham equation.20 
Cardiovascular risk scores (risk of cardiovascular 
disease in five years) were grouped as follows: mild 
(0–10%), moderate and high (10–20%), and very 
high (>20%), as per the New Zealand Cardiovascu-
lar Guidelines grouping.19 A patient’s cardiovascu-
lar risk score was incremented by five percentage 
points if he/she fulfilled either or both of the fol-
lowing criteria: Maori/Pacific ethnicity, or family 
history of premature cardiovascular disease.
A previous audit was carried out in the South 
Auckland practice in March 2009. This audit 
studied the impact of an active intervention 
over the course of a year, to up-titrate allopuri-
nol in order to achieve a target SUA level <0.36 
mmol/L. Patients identified for inclusion were 
those with a classification of gout, or prescrip-
tion of allopurinol, colchicine or probenecid. 
This current audit did not include a prescription 
of probenecid in its identification of patients, 
as only one patient was prescribed this in the 
South Auckland practice at the time of the 2009 
audit. This study then compared the results of 
the audit in March 2009 with the results of this 
study’s audit, to determine if control of gout had 
improved with time.
Results of assessment/measurement
A total of 196 patients qualified for inclusion 
in the audit. One patient was excluded due to a 
diagnosis of myeloproliferative disease and no 
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WHAT GAP THIS FILLS
What we already know: Gout is a common inflammatory arthritis, af-
fecting the Maori and Pacific population in particular. Cardiovascular risk 
assessment should be completed alongside a diagnosis of gout, due to the 
comorbidities associated with gout. 
What this study adds: Gout may be being suboptimally managed in pri-
mary care and annual serum uric acid levels should be completed. Cardiovas-
cular risk management in primary care may also be suboptimal for this group 
of patients. 
mention of gout in their notes. The percentage of 
patients with gout in the total practice popula-
tion was 4.2% (196/4641). This audit found that 
9.5% of men in the practice population have gout. 
Furthermore, 94% (60/64) of the women in the 
audit were aged over 50 years, emphasising that 
gout predominantly appears in post-menopausal 
women. This audit found that Maori women were 
on average 11 years younger than their European 
counterparts. Table 1 provides a comparison of 
patient characteristics.
Despite the majority having a formal classifica-
tion of gout, 5.1% (10/196) had no record in their 
notes of an SUA ever being measured. This 
study found that, in comparison to the previ-
ous audit performed in March 2009, there has 
been a significant increase (p=0.009) in the mean 
SUA level (Table 2). This study also found that 
there was a non-significant decrease (p=0.08) in 
the proportion of patients with an SUA level 
≤0.36 mmol/L. 
Table 3 provides a summary of the cardiovascu-
lar risk scores and individual risk factor target 
achievement for this group of patients. On 
further analysis, 47% of patients with hyper-
uricaemia (SUA level >0.36 mmol/L) had an 
SBP >130 mm Hg. In total, 36% (68/189) of the 
sample population had a high or very high risk 
of cardiovascular disease. As a consequence of 
this finding, this study assessed whether the 
New Zealand targets for cardiovascular risk 
factors were being achieved. Of note, only 26% 
of patients with a very high cardiovascular risk 
score had achieved a target SBP of <130 mm Hg. 
For all cardiovascular risk groups, target SBP was 
achieved by the lowest proportion of patients 
compared with the proportion of patients achiev-
ing other recommended targets. Other recom-
mended targets included achieving a target HDL 
>1 mmol/L, a target HbA1c ≤53 mmol/mol and 
smoking cessation. The very high cardiovascular 
risk group was less successful than the lower 
cardiovascular risk groups in achieving recom-
mended cardiovascular risk targets. The highest 
proportion of patients achieving target SBP were 
those with a less than 15% risk of cardiovascular 
disease in five years. Of note, only 28% (19/68) 
of patients in the very high cardiovascular risk 
group were achieving the target SUA level. 
Table 1. Patient characteristics (N=196)
Characteristic
Mean age 61.2 years (range, 26–95 years)
Gender Male 67% (132/196)
Female 33% (64/196)
Ethnicity European 52% (101/196)
Maori 28% (54/196)
Pacific 15% (30/196)
Other 6% (11/196)
NZDep2006* Quintile 1 14% (27/196)
Quintile 2 11% (22/196)
Quintile 3 10% (19/196)
Quintile 4 18% (35/196)
Quintile 5 47% (92/196)
NZDep2006  New Zealand Index of Deprivation 2006
*  One patient was undefined according to the NZDep2006
Table 2. Comparison of the control of gout (SUA ≤0.36 mmol/L) between this audit (2012) 
and a previous audit in 2009
Gout audit 
March 2009
(N=36)
Gout audit 
November 2012
(N=186)
P-value for comparison 
(2009 with 2012 values) 
and statistical test used
Mean SUA 0.36 0.41 p=0.009; t test
Range SUA 0.18–0.57 0.13–0.68
Median SUA 0.345 0.41 p=0.08; Chi-squared test
% ≤0.36 SUA 50% 34.7%
SUA  Serum uric acid level
Strategies for quality 
improvement/change
Regarding the frequency of SUA measure-
ment, the general consensus is that annual SUA 
measurement would be beneficial in predicting 
the likelihood of future gout attacks and, in 
certain patients, would allow the introduction of 
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urate-lowering therapy.21,22 The South Auckland 
practice that was audited had stopped carrying 
out three-monthly SUA testing and had not 
instigated any other form of regular uric acid 
testing. The practice of only measuring uric acid 
level in acute gout attacks is counterintuitive, 
given that in the majority of cases SUA level is 
low or normal.23 Regular SUA testing would af-
ford an opportunity to assess patient medication 
compliance, which, given the use of alterna-
tive remedies and over-the-counter medication 
amongst the Maori and Pacific communities, may 
be worthwhile.14 Suboptimal management of gout 
may also be influenced by the health literacy of 
patients. Korero Marama found that Maori have 
poorer health literacy skills compared with non-
Maori.24 This could have a significant impact, in 
terms of patients not appreciating the need for 
long-term medication and how to manage gout as 
a chronic condition.
Overall the practice performed poorly in terms 
of gout management, with only 19.9% of the 
patients in the sample achieving the target SUA 
level in the past year. This suggests that, despite 
more than half of patients having an SUA meas-
urement in the past year, gout continues to be 
poorly controlled. Nevertheless, in comparison to 
the audit in 2009, there has been an increase in 
the proportion of patients prescribed allopurinol. 
Despite this improvement, allopurinol dosing 
is still suboptimal, as only half of the patients 
recently prescribed allopurinol achieved the 
target SUA level. A common concern of practi-
tioners is worsening of renal impairment in those 
with gout by increasing the dose of allopurinol. 
Table 4 provides a summary comparison between 
those patients prescribed allopurinol and those 
patients who were not, with their SUA level. The 
suboptimal management of gout despite allopu-
rinol therapy has also been reported in the UK 
and Germany.2 The ultimate therapeutic aim of 
prescribing allopurinol is to cause dissolution and 
prevent formation of urate crystals; this opti-
mally happens at an SUA level ≤0.36 mmol/L. To 
ensure this level is reached, consideration should 
be given to the instigation of dedicated primary 
care nurses to manage gout and its associated 
comorbidities, as has been implemented in the 
management of diabetes, with some success.25 
Recently published guidelines have recommended 
screening for hyperlipidaemia, hypertension and 
diabetes when making decisions about the man-
agement of gout.10 In our study, 26% of patients 
with a very high cardiovascular risk had not 
been prescribed allopurinol. This finding raises 
Table 4. Comparison of mean SUA level and proportion at the target SUA ≤0.36 mmol/L for the total patient group and 
according to whether allopurinol prescribed for use
Patients (N=196)
Currently prescribed 
allopurinol* (n=92)
Never prescribed 
allopurinol (n=70)
Mean SUA level 0.41 mmol/L 0.37 mmol/L 0.45 mmol/L
Number at target 
SUA ≤0.36 mmol/L 35% (68/196)† 50% (46/92) 13% (9/70)
SUA  serum uric acid level
*  Taken as being prescribed in the past three months
†  Nine patients had not had an SUA measurement 
Table 3. Summary of cardiovascular risk scores for the total group (n=189)* and proportion 
of the group achieving the individual cardiovascular risk factor targets
CV risk score
CV risk 0–<10% 39% (74/189)
CV risk 10–<20% 40% (76/189)
CV risk >20% 21% (39/189)
Individual risk factor targets†
Target SBP <130 mm Hg 44% (83/189)
Target HDL cholesterol >1 mmol/L 71% (134/189)
Target HbA1c <53 mmol/L 85% (160/189)
CV  Cardiovascular
SBP  Systolic blood pressure
HDL  High density lipoprotein
HbA1c  Haemoglobin A1c
*  Seven patients could not be given a cardiovascular risk score as certain values were unrecorded
†  Data were not recorded for all individual risk factor targets for all patients included in the study 
(N=196)
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concern given reports that indicate that gout may 
increase the risk of acute myocardial infarction.26 
Optimal management of gout, particularly in 
patients with a very high cardiovascular risk, is 
thus necessary. Research carried out in second-
ary care suggests that patients with gout in this 
setting would benefit from cardiovascular risk 
management.17 However, given the high risk of 
comorbidities associated with gout, this study 
further emphasises the need for cardiovascu-
lar risk assessment and management as part of 
primary care management of gout.16,27 This is 
in agreement with recently published EULAR 
recommendations and research on the manage-
ment of gout.2,10 An initial assessment of a 
patient’s cardiovascular risk should be carried out 
on diagnosis of gout and, from there, follow-up 
should be based on the level of risk, according to 
New Zealand Cardiovascular Guidelines.19 This 
allows not only for better control of comorbidi-
ties, with modifiable risk factors being identi-
fied early, but also a holistic approach to be 
adopted with regard to patient care. This could be 
achieved by primary care practitioners allowing 
an extended consultation time with the patient 
on first presentation of gout, to afford an oppor-
tunity for all components of the patient’s care to 
be addressed.28 Given the high prevalence of gout 
in Maori and Pacific people, with an additional 
increased cardiovascular risk, it is important to 
include an assessment of cardiovascular risk with 
a diagnosis of gout in this patient group.7,17,19 
Following the audit, results were provided as 
feedback to relevant staff at the primary care 
practice at which the audit was based. After some 
discussion, it was proposed that patients with 
gout should have a repeat uric acid level taken, 
with follow-up appointments to be arranged if 
the result was abnormal.
Lessons and messages
Despite interventions, gout continues to be 
poorly controlled in this South Auckland prac-
tice. However, with the introduction of annual 
measurement of SUA level, lack of compliance 
with medication and forewarning of future gout 
attacks will be identified. This study highlights 
that practitioners need to be aware of the increas-
ing evidence of high-risk comorbidities associated 
with gout. Our results also suggest that there 
is a lack of allopurinol up-titration, in order to 
achieve the target SUA level. Therefore, primary 
care physicians should review the dose of allopu-
rinol in patients with gout that is persistently 
poorly controlled. Consideration should be given 
to the use of dedicated primary care nurses in the 
management of gout. Alternatively an extended 
consultation time with the practitioner would 
allow cardiovascular risk assessment and manage-
ment to be carried out as part of the primary care 
management of gout on first presentation. This 
would allow the adoption of a holistic approach 
to patient care and modifiable cardiovascular risk 
factors to be addressed earlier. 
There needs to be recognition of the impact of 
gout on the health of patients in South Auckland 
and of its implications for the future financial 
burden on the health care system. Improved 
management of gout in primary care will permit 
secondary care resources to be more appropriately 
distributed.
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